Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Discover high-quality research tools to investigate GLP-1 mechanisms and next-generation metabolic targets.
OBESITY RESEARCH SOLUTIONSSotagliflozin is an inhibitor of sodium-glucose cotransporters (SGLTs; IC50s = 36 and 1.8 nM for human SGLT1 and SGLT2, respectively).1 It increases plasma glucagon-like peptide 1 (GLP-1) and peptide YY (PYY) levels, as well as glucose levels in the small intestine, cecum, and colon, in mice when administered at a dose of 60 mg/kg.2 Sotagliflozin (2 and 30 mg/kg) decreases blood glucose levels in a mouse model of diabetes induced by cyclophosphamide (Item No. 13849).3 Formulations containing sotagliflozin have been used in the treatment of type 1 diabetes.
WARNING This product is not for human or veterinary use.
1. LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-
2. LX4211 increases serum glucagon-
3. Sotagliflozin improves glycemic control in nonobese diabetes-